Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.
The renin-angiotensin system has been shown to have an effect on erythropoietin synthesis and hemoglobin concentration. We present a retrospective study of stable renal transplant recipients who received an angiotensin-converting enzyme (ACE) inhibitor as treatment of hypertension. Fifteen patients were eligible, with a mean hemoglobin concentration of 130.7 +/- 22.7 g/L (SD). Within 6 months of ACE-inhibitor therapy, the mean hemoglobin had fallen significantly to 110.5 +/- 23.2 g/L (p less than 0.001). No parallel change in leukocyte or platelet counts was evident. Prospective studies are needed to clarify the effect of inhibition of the renin-angiotensin system on erythropoietin synthesis and release.
Sizeland
P C
PC
Department of Nephrology, Christchurch Hospital, New Zealand.
Bailey
R R
RR
Lynn
K L
KL
Robson
R A
RA
D000740:Anemia / Q000097:blood / Q000139:chemically induced*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004656:Enalapril / Q000009:adverse effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D016030:Kidney Transplantation / Q000502:physiology*; D007958:Leukocyte Count; D010976:Platelet Count
D000806:Angiotensin-Converting Enzyme Inhibitors; D006454:Hemoglobins; D004656:Enalapril